Lv4
470 积分 2021-12-30 加入
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies
16小时前
待确认
[Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)]
20天前
已完结
Mezigdomide for multiple myeloma: a focus on phase 2 trial data
27天前
已完结
Minimal Residual Disease in Multiple Myeloma
1个月前
已完结
Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis
1个月前
已完结
Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
1个月前
已完结
Emerging immunotherapies in multiple myeloma
1个月前
已完结
Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
2个月前
已完结
Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma
2个月前
已完结
Mezigdomide and Multiple Myeloma
2个月前
已完结
皖公网安备34019202002308
